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of RVR in deciding whether genotype 2/3-infected patients
should receive short-term treatment. Additionally, considering
that sampling HCV RNA on day 7 entails only one sampling
instead of the two suggested by Sarrazin et al., i.e. baseline and
week 4, while identifying approximately as many suitable candi-
dates for short-term therapy, sampling at day 7 is likely to be
more cost-effective for patients infected with HCV genotype 2
or 3. Also, the suggested cut-off level of 1000 IU/ml is stably
quantiﬁable by most currently available assays, and is not prone
to re-deﬁnition as the limits of detection of HCV RNA analyses
will further improve over time. Similarly, since it is important
that the day 7 HCV RNA sample is drawn immediately prior to
the second dose of pegylated interferon, this allows for an
additional opportunity to directly observe the patient’s injection
technique as well as minimize the risk of sampling variations in
relation to the previous dose as is often the case with week 4
HCV RNA determination. However, it is important to consider
the intra- and inter-assay variability of real-time PCR based HCV
RNA assays [6] as well as differences between methods that
persist despite the introduction of WHO standardizations [7],
which obviously affect all proposed algorithms based on quantita-
tive HCV RNA determinations, including those at baseline or day 7.
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Letters to the EditorViral kinetics for individualized treatment durationsReply to Lagging et al.:
The shortening of treatment duration is the most important aim
for improving antiviral therapy in patients with chronic hepatitis
C. The new direct antiviral agents currently in development
should allow an increasing number of patients to beneﬁt from
shortened treatment durations and consequently to signiﬁcantly
increase the number of patients who are willing and able to
receive antiviral therapy. Algorithms for abbreviated treatment
durations established for the current standard of care are mainly
based on viral kinetics. In addition, while not visible in smaller
studies [1,2] all large studies have shown that in patients with
high baseline viral load, higher relapse rates were observed,
although they become HCV RNA negative at time points that836 Journal of Hepatology 20are identical to those reported in patients with a low baseline
viral load [3,4]. Thus, in the NORDynamIC study reported by Lag-
ging et al., baseline viral load may not be a signiﬁcant predictor of
relapse in patients with virologic response at day 7 because of the
limited number of patients investigated [5]. However, it may also
be that the selection of patients for shortened treatment very
early on during therapy (i.e. day 7) and the application of a viral
cut-off level (i.e. 1000 IU/ml) rather than undetectable HCV RNA,
allow for a response to be predicted independent of baseline viral
load. This has to be explored in future studies. However, while
the assessment of virologic response very early during therapy
may indeed have the potential of very high positive predictive
values of sustained virologic response, the number of patients11 vol. 54 j 835–839
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beneﬁtting may decline (i.e. 109 vs. 136 patients in the NORDy-
namIC trial). In addition, practical, pharmacokinetic, and techni-
cal problems may arise: (1) it is essential to take an early
assessment of viral kinetic measurements of HCV RNA viral load
from blood drawn exactly at day 7 and directly before the next
PEG-interferon injection because viral load may ﬂuctuate signiﬁ-
cantly during the initial phase of viral decline. This may be less of
a problem 4 weeks after initiation of antiviral therapy. Indeed, in
our study we found that when retesting a large number of sam-
ples at week 4, undetectable HCV RNA and viral levels below
15 IU/ml had identical predictive values for sustained virologic
response in genotype 1 and 2/3 infected patients [6]. (2) Differ-
ences may be present between the two pegylated interferons alfa
2a and 2b because of different pharmacokinetics (65 vs. a 28 h
elimination half-life, respectively). For pegylated interferon alfa
2b, a more step-wise viral decline is well known. After one week
of therapy a ﬂat or even slightly increasing viral load kinetics may
be seen while a more continuous viral decline is observed with
pegylated interferon alfa 2a. With identical rapid virologic
response rates for both pegylated interferons at week 4 of treat-
ment (IDEAL study 11.4% vs. 11.9% for pegylated interferon alfa
2a vs. 2b, respectively) [7] algorithms with later assessments of
virologic response may be better applicable for these differences.
(3) Finally, despite standardization of IU HCV RNA viral loads
measured with different commercially available assays, these
are not comparable and this is already a problem for the determi-
nation of low vs. high baseline viral load. For a measurement at
day 7 as proposed by Lagging et al., for example 1000 IU/ml by
the Cobas TaqMan assay in genotype 1, 2, 3 infected patients
equals approximately 300, 1000, and 600 IU/ml by realtime
HCV and 300, 600, and 500 IU/ml by the bDNA assay [8–11].
Moreover, a signiﬁcant intra- and inter-assay variability espe-
cially for lower viral loads (0.04–0.13 log10 SD) may make it dif-
ﬁcult to establish a general and precise rule with just one HCV
RNAmeasurement taken early during therapy [10]. Herein, deter-
mination of undetectable HCV RNA levels with a highly sensitive
assay may be superior because all new assays have lower detec-
tion limits between 5 and 10 IU/ml (Cobas TaqMan, realtime HCV,
TMA).
All these parameters have to be taken into account for the cur-
rent standard of care. In the era of direct antiviral agents that dis-
play strong antiviral activities, highly individualized and tailored
treatment durations will be established. The determination of
virologic response with or without additional parameters (base-
line viral load, IL28B polymorphisms etc.) very early during ther-
apy (i.e. between day 3 and week 4) will most likely be required
for the selection of super responders that may beneﬁt from very
short treatments (24 weeks or shorter for genotype 1 and perhaps
even below 12–16 weeks for genotype 2/3 infected patients).Reactivation of autoimm
budesonide monotherapy, and r
To the Editor:
The large European trial of budesonide therapy suggests that
budesonide might be better than prednisone in the treatment
of newly diagnosed autoimmune hepatitis [1]. These results were
based on the sensible combination of azathioprine and steroid,
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esponse to standard treatment
but already physicians have started using budesonide mono-
therapy, or combinations of budesonide and prednisone or pred-
nisolone. We wish to report a case of autoimmune hepatitis
(AIH), who experienced reactivation of disease activity during
treatment with 3  3 mg budesonide per day and tapering doses
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